Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific ABCA7 ABCX ENSG00000064687 ATP-binding cassette, sub-family A (ABC1), member 7 19 1040101-1065572 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041564 Supported Supported Golgi apparatus
Plasma membrane
Cell Junctions Endometrial cancer:1.12e-4 (favourable), Colorectal cancer:7.26e-4 (unfavourable) Expressed in all Mixed spleen: 25.8 ABCC5 EST277145, MOAT-C, MRP5, SMRP ENSG00000114770 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 3 183919934-184018015 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA044067, HPA052295 Uncertain Supported Nucleus
Plasma membrane
Cell Junctions Liver cancer:6.78e-8 (unfavourable), Prostate cancer:3.40e-4 (unfavourable) Expressed in all Expressed in all stomach: 72.0 ABI1 ABI-1, E3B1, SSH3BP1 ENSG00000136754 Abl-interactor 1 10 26746593-26861087 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB008375, HPA029973, HPA068407 Approved Supported Plasma membrane
Cell Junctions Expressed in all Expressed in all cerebral cortex: 87.6 ABLIM3 KIAA0843 ENSG00000173210 Actin binding LIM protein family, member 3 5 149141483-149260542 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003245 Approved Approved Nucleoplasm
Plasma membrane
Cell Junctions Renal cancer:1.28e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 78.1 adipose tissue: 63.4 ACOT13 HT012, THEM2 ENSG00000112304 Acyl-CoA thioesterase 13 6 24667035-24705065 Predicted intracellular proteins Evidence at protein level HPA019881 Approved Approved Cell Junctions Ovarian cancer:2.53e-6 (favourable) Expressed in all Expressed in all kidney: 20.9 ADAM22 MDC2 ENSG00000008277 ADAM metallopeptidase domain 22 7 87934143-88202889 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050325 Approved Cell Junctions Mixed Tissue enhanced cerebral cortex: 47.7 prostate: 17.5 ADGRL2 KIAA0786, LEC1, LPHH1, LPHN2 ENSG00000117114 Adhesion G protein-coupled receptor L2 1 81306160-81992436 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA043447 Approved Plasma membrane
Cell Junctions Endometrial cancer:1.33e-4 (unfavourable), Stomach cancer:3.00e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable) Expressed in all Mixed thyroid gland: 72.8 AGER RAGE ENSG00000204305 Advanced glycosylation end product-specific receptor 6 32180968-32184324 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB011682, HPA064436 Approved Approved Nucleoli fibrillar center
Plasma membrane
Cell Junctions Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable) Expressed in all Tissue enriched 181 lung: 891.2 thyroid gland: 4.9 AGO2 EIF2C2, hAGO2, Q10 ENSG00000123908 Argonaute RISC catalytic component 2 8 140520156-140635619 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB019309, HPA058075 Approved Supported Nucleoplasm
Cell Junctions Renal cancer:1.82e-5 (unfavourable), Endometrial cancer:1.21e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 11.9 AMOTL1 JEAP ENSG00000166025 Angiomotin like 1 11 94706431-94876753 Predicted intracellular proteins Evidence at protein level HPA001196 Approved Supported Cell Junctions
Cytosol Renal cancer:5.03e-6 (favourable) Expressed in all Expressed in all prostate: 52.2 AMOTL2 LCCP ENSG00000114019 Angiomotin like 2 3 134355874-134375479 Predicted intracellular proteins Evidence at protein level HPA063027 Approved Cell Junctions
Centrosome Endometrial cancer:1.94e-4 (unfavourable) Expressed in all Mixed adipose tissue: 76.4 ANKRA2 ENSG00000164331 Ankyrin repeat, family A (RFXANK-like), 2 5 73552335-73565686 Predicted intracellular proteins Evidence at protein level HPA065263 Approved Plasma membrane
Cell Junctions Expressed in all Expressed in all thyroid gland: 26.1 AQP4 MIWC ENSG00000171885 Aquaporin 4 18 26852038-26865818 Predicted membrane proteins, Transporters Evidence at protein level CAB005079, HPA014784, CAB058689 Supported Supported Supported Plasma membrane
Cell Junctions Tissue enriched Group enriched 17 cerebral cortex: 631.8;lung: 172.2 thyroid gland: 24.3 ARHGAP21 ARHGAP10, KIAA1424 ENSG00000107863 Rho GTPase activating protein 21 10 24583609-24723668 Predicted intracellular proteins Evidence at protein level HPA036610, HPA057861 Approved Supported Plasma membrane
Cell Junctions
Actin filaments Expressed in all Expressed in all cerebral cortex: 103.8 ARHGAP28 FLJ10312, KIAA1314 ENSG00000088756 Rho GTPase activating protein 28 18 6729718-6915716 Predicted intracellular proteins Evidence at protein level HPA030413, HPA030414, HPA030415 Supported Supported Cell Junctions Mixed Tissue enhanced testis: 132.2 placenta: 40.5 ARL15 ARFRP2, FLJ20051 ENSG00000185305 ADP-ribosylation factor-like 15 5 53883945-54310582 Predicted intracellular proteins Evidence at protein level HPA044604, HPA063820 Uncertain Approved Golgi apparatus
Plasma membrane
Cell Junctions Expressed in all Expressed in all placenta: 44.4 ARPC1A Arc40, SOP2Hs, SOP2L ENSG00000241685 Actin related protein 2/3 complex, subunit 1A, 41kDa 7 99325898-99388164 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004334 Approved Approved Cell Junctions
Cytosol Liver cancer:4.70e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 131.0 ARPC5 ARC16, dJ127C7.3, p16-Arc ENSG00000162704 Actin related protein 2/3 complex, subunit 5, 16kDa 1 183620846-183635757 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA022013, HPA031972 Approved Approved Vesicles
Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.21e-10 (unfavourable), Liver cancer:3.63e-4 (unfavourable) Expressed in all Expressed in all appendix: 207.6 ARVCF ENSG00000099889 Armadillo repeat gene deleted in velocardiofacial syndrome 22 19969896-20016808 Predicted intracellular proteins Evidence at protein level CAB016162, HPA055264, HPA063675 Approved Supported Nuclear speckles
Plasma membrane
Cell Junctions Urothelial cancer:5.76e-6 (favourable) Expressed in all Mixed spleen: 9.0 ASGR1 CLEC4H1 ENSG00000141505 Asialoglycoprotein receptor 1 17 7173431-7179564 Predicted intracellular proteins Evidence at protein level HPA011954, HPA012852 Supported Supported Vesicles
Cell Junctions Tissue enriched Tissue enriched 13 liver: 236.1 testis: 17.7 BRK1 C3orf10, HSPC300, MDS027 ENSG00000254999 BRICK1, SCAR/WAVE actin-nucleating complex subunit 3 10115592-10127190 Predicted intracellular proteins Evidence at protein level HPA060391 Approved Nuclear speckles
Cell Junctions Liver cancer:5.76e-5 (unfavourable) Expressed in all Expressed in all fallopian tube: 223.3 BVES HBVES, POP1, POPDC1 ENSG00000112276 Blood vessel epicardial substance 6 105096822-105137174 Predicted membrane proteins Evidence at protein level HPA014788, HPA018176 Supported Supported Cell Junctions Mixed Tissue enhanced smooth muscle: 24.7 testis: 20.7 C11orf52 FLJ25219, MGC14839 ENSG00000149300 Chromosome 11 open reading frame 52 11 111918032-111926872 Predicted intracellular proteins Evidence at protein level HPA038387, HPA038388 Uncertain Validated Cell Junctions Not detected Mixed kidney: 44.8 C16orf59 FLJ13909 ENSG00000162062 Chromosome 16 open reading frame 59 16 2460080-2464963 Predicted intracellular proteins Evidence at protein level HPA051394 Uncertain Approved Nucleoplasm
Cell Junctions Liver cancer:2.43e-5 (unfavourable), Lung cancer:7.58e-4 (unfavourable) Expressed in all Tissue enhanced testis: 5.5 lymph node: 2.6 C17orf104 FLJ35848 ENSG00000180336 Chromosome 17 open reading frame 104 17 44656404-44690308 Predicted intracellular proteins Evidence at protein level HPA027266 Uncertain Uncertain Cell Junctions Not detected Tissue enriched 51 testis: 85.8 cerebral cortex: 1.6 C17orf62 FLJ90469, MGC4368 ENSG00000178927 Chromosome 17 open reading frame 62 17 82442589-82450829 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045696 Uncertain Approved Plasma membrane
Cell Junctions Renal cancer:6.83e-11 (unfavourable) Expressed in all Expressed in all lymph node: 129.5 C4orf19 FLJ11017 ENSG00000154274 Chromosome 4 open reading frame 19 4 37453941-37623495 Predicted intracellular proteins Evidence at protein level HPA043458, HPA052894 Approved Supported Cell Junctions Renal cancer:1.49e-11 (favourable) Mixed Mixed rectum: 27.4 C8orf37 CORD16, FLJ30600, RP64 ENSG00000156172 Chromosome 8 open reading frame 37 8 95244919-95269201 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA024198 Approved Approved Plasma membrane
Cell Junctions
Cytosol Endometrial cancer:4.63e-4 (unfavourable) Expressed in all Mixed fallopian tube: 6.3 C9orf3 AOPEP, AP-O, APO, C90RF3, FLJ14675 ENSG00000148120 Chromosome 9 open reading frame 3 9 94726701-95087218 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004633, HPA072729 Approved Approved Cell Junctions Renal cancer:6.33e-5 (favourable) Expressed in all Expressed in all skin: 50.1 CABLES2 C20orf150, dJ908M14.2, ik3-2 ENSG00000149679 Cdk5 and Abl enzyme substrate 2 20 62388632-62407285 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052138 Approved Nuclear bodies
Cell Junctions Renal cancer:1.24e-6 (unfavourable), Endometrial cancer:5.26e-5 (unfavourable) Expressed in all Tissue enriched 6 testis: 58.3 cerebral cortex: 9.0 CADM1 BL2, IGSF4, IGSF4A, Necl-2, NECL2, RA175, ST17, SYNCAM, SYNCAM1, TSLC1 ENSG00000182985 Cell adhesion molecule 1 11 115169218-115504957 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037266 Supported Supported Cell Junctions Endometrial cancer:1.32e-4 (favourable) Expressed in all Mixed parathyroid gland: 119.5 CAMK2A CAMKA, CaMKIINalpha, KIAA0968 ENSG00000070808 Calcium/calmodulin-dependent protein kinase II alpha 5 150219491-150290291 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004330, HPA051783, HPA051785, HPA053973 Supported Supported Plasma membrane
Cell Junctions Tissue enriched Tissue enriched 9 cerebral cortex: 284.4 skeletal muscle: 33.3 CAMK2B CAM2, CAMK2, CAMKB ENSG00000058404 Calcium/calmodulin-dependent protein kinase II beta 7 44217150-44334577 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006849, HPA026307, HPA051783, HPA051785, HPA053973 Supported Supported Uncertain Plasma membrane
Cell Junctions Mixed Tissue enhanced cerebral cortex: 214.7 skeletal muscle: 46.1 CAMK2D CAMKD ENSG00000145349 Calcium/calmodulin-dependent protein kinase II delta 4 113451032-113761927 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026281, HPA051783, HPA051785, HPA053973 Approved Supported Plasma membrane
Cell Junctions Expressed in all Expressed in all parathyroid gland: 106.2 CAMK2G CAMKG ENSG00000148660 Calcium/calmodulin-dependent protein kinase II gamma 10 73812501-73874591 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040656, HPA051783, HPA051785, HPA053973 Approved Approved Plasma membrane
Cell Junctions
Cytosol Expressed in all Expressed in all cerebral cortex: 119.4 CCDC170 bA282P11.1, C6orf97, FLJ23305 ENSG00000120262 Coiled-coil domain containing 170 6 151494030-151621193 Predicted intracellular proteins Evidence at protein level HPA027114, HPA027185 Supported Approved Golgi apparatus
Cell Junctions Endometrial cancer:3.64e-4 (favourable) Mixed Tissue enriched 6 fallopian tube: 52.9 thyroid gland: 9.4 CCDC66 DKFZp686C0433 ENSG00000180376 Coiled-coil domain containing 66 3 56557161-56621818 Predicted intracellular proteins Evidence at protein level HPA044185 Uncertain Approved Cell Junctions
Midbody ring
Microtubule organizing center Expressed in all Mixed fallopian tube: 9.5 CCDC85C ENSG00000205476 Coiled-coil domain containing 85C 14 99500180-99604026 Predicted intracellular proteins Evidence at protein level HPA058346 Uncertain Approved Nuclear speckles
Cell Junctions Renal cancer:2.60e-5 (favourable), Endometrial cancer:1.44e-4 (unfavourable) Expressed in all Expressed in all esophagus: 31.3 CD34 ENSG00000174059 CD34 molecule 1 207880972-207911402 CD markers, Predicted membrane proteins Evidence at protein level CAB000018, HPA036722, HPA036723 Supported Approved Nucleus
Plasma membrane
Cell Junctions Head and neck cancer:5.93e-5 (favourable), Renal cancer:8.47e-4 (unfavourable) Expressed in all Expressed in all placenta: 313.8 CDH1 CD324, UVO, uvomorulin ENSG00000039068 Cadherin 1, type 1 16 68737225-68835548 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857 Supported Supported Golgi apparatus
Plasma membrane
Cell Junctions Renal cancer:2.06e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 467.0 thyroid gland: 264.7 CDH17 cadherin, HPT-1 ENSG00000079112 Cadherin 17, LI cadherin (liver-intestine) 8 94127171-94217303 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA023614, HPA023616, CAB025143, HPA026556 Supported Supported Cell Junctions Group enriched Group enriched 7 colon: 261.7;duodenum: 323.0;rectum: 272.5;small intestine: 300.5 appendix: 39.2 CDH2 CD325, CDHN, NCAD ENSG00000170558 Cadherin 2, type 1, N-cadherin (neuronal) 18 27950966-28177446 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000141, CAB018580, HPA058574 Supported Supported Plasma membrane
Cell Junctions Expressed in all Tissue enhanced heart muscle: 125.8;parathyroid gland: 124.0 adrenal gland: 87.7 CDH3 CDHP, PCAD ENSG00000062038 Cadherin 3, type 1, P-cadherin (placental) 16 68636189-68722616 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001767, CAB002487 Supported Uncertain Cell Junctions
Cytosol Pancreatic cancer:8.43e-4 (unfavourable), Lung cancer:8.53e-4 (unfavourable) Mixed Tissue enhanced skin: 32.0 ovary: 26.9 CDK5 PSSALRE ENSG00000164885 Cyclin-dependent kinase 5 7 151053812-151058530 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB008909, HPA018977, HPA064535 Approved Supported Nucleus
Plasma membrane
Cell Junctions
Cytosol Expressed in all Expressed in all cerebral cortex: 50.0 CDK5RAP2 C48, CEP215, FLJ10867, MCPH3 ENSG00000136861 CDK5 regulatory subunit associated protein 2 9 120388869-120580170 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035820, HPA046529 Approved Validated Cell Junctions
Centrosome Expressed in all Expressed in all testis: 37.2 CDRT15 ENSG00000223510 CMT1A duplicated region transcript 15 17 14235673-14236862 Predicted intracellular proteins Evidence at protein level HPA055952 Uncertain Approved Cell Junctions Not detected Tissue enhanced testis: 11.6 skin: 4.0 CERCAM CEECAM1, CerCAM, GLT25D3 ENSG00000167123 Cerebral endothelial cell adhesion molecule 9 128411751-128437351 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021657, HPA051595 Uncertain Approved Nucleus
Nucleoli
Cell Junctions Renal cancer:3.33e-16 (unfavourable), Urothelial cancer:3.30e-5 (unfavourable), Ovarian cancer:5.22e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 156.0 CFAP206 C6orf165, dJ382I10.1, FLJ25974 ENSG00000272514 Cilia and flagella associated protein 206 6 87407983-87464465 Predicted intracellular proteins Evidence at protein level HPA044891, HPA072261 Approved Approved Nucleoplasm
Cell Junctions Not detected Group enriched 30 fallopian tube: 35.3;testis: 107.4 lung,thyroid gland: 2.3 CFB BF, BFD, H2-Bf ENSG00000243649 Complement factor B 6 31945650-31952084 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000951, HPA001817, HPA001832, CAB016381 Supported Uncertain Vesicles
Cell Junctions Renal cancer:1.53e-5 (unfavourable), Breast cancer:2.76e-5 (favourable) Expressed in all Tissue enriched 20 liver: 283.0 stomach: 13.9 CGN KIAA1319 ENSG00000143375 Cingulin 1 151510510-151538692 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017193, HPA027586, HPA027587, HPA027657 Supported Supported Plasma membrane
Cell Junctions Renal cancer:5.84e-10 (favourable) Expressed in all Tissue enhanced parathyroid gland: 73.3 small intestine: 63.2 CGNL1 FLJ14957, JACOP, KIAA1749, paracingulin ENSG00000128849 Cingulin-like 1 15 57375967-57550727 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB013500, HPA056911, HPA069214 Supported Approved Cell Junctions Renal cancer:1.37e-6 (favourable), Endometrial cancer:3.55e-4 (favourable), Liver cancer:5.58e-4 (favourable) Expressed in all Mixed kidney: 72.7 CHCHD7 COX23, MGC2217 ENSG00000170791 Coiled-coil-helix-coiled-coil-helix domain containing 7 8 56211686-56218798 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA050783 Approved Approved Cell Junctions
Aggresome Endometrial cancer:1.39e-6 (unfavourable), Renal cancer:9.47e-5 (favourable) Expressed in all Expressed in all ovary: 61.5 CLCA2 CLCRG2 ENSG00000137975 Chloride channel accessory 2 1 86424086-86456558 Predicted membrane proteins Evidence at protein level HPA047192 Supported Supported Nucleus
Cell Junctions Group enriched Tissue enhanced esophagus: 126.9;skin: 102.9 tonsil: 23.5 CLDN2 ENSG00000165376 Claudin 2 X 106900164-106930861 Predicted membrane proteins Evidence at protein level CAB002609, HPA051548 Supported Supported Nucleoplasm
Cell Junctions Thyroid cancer:1.70e-4 (favourable) Group enriched Tissue enhanced gallbladder: 159.7;kidney: 170.5;seminal vesicle: 128.0 epididymis: 40.4 CLDN3 C7orf1, CPE-R2, CPETR2, HRVP1, RVP1 ENSG00000165215 Claudin 3 7 73768997-73770270 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002702, HPA014361 Supported Supported Cell Junctions Renal cancer:3.39e-5 (favourable) Mixed Tissue enhanced colon: 89.6;small intestine: 121.9 duodenum: 56.5 CLDN7 CEPTRL2, CPETRL2, Hs.84359 ENSG00000181885 Claudin 7 17 7259903-7263983 Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB013063, HPA014703, HPA073662 Supported Approved Vesicles
Cell Junctions Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable) Expressed in all Mixed small intestine: 357.1 CLDN9 ENSG00000213937 Claudin 9 16 3012456-3014505 Predicted membrane proteins Evidence at protein level HPA076613 Supported Vesicles
Cell Junctions Endometrial cancer:2.24e-6 (unfavourable), Stomach cancer:4.67e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 3.1 bone marrow: 1.7 CMTR2 AFT, FLJ11171, FTSJD1, MTr2 ENSG00000180917 Cap methyltransferase 2 16 71281389-71289715 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041700, HPA048265 Uncertain Approved Nuclear speckles
Cell Junctions Renal cancer:4.97e-5 (favourable) Expressed in all Mixed testis: 16.2 COBL KIAA0633 ENSG00000106078 Cordon-bleu WH2 repeat protein 7 51016212-51316818 Predicted intracellular proteins Evidence at protein level HPA019033, HPA019167 Supported Approved Plasma membrane
Cell Junctions Renal cancer:5.21e-12 (favourable) Mixed Mixed cerebral cortex: 61.6 COLEC12 CL-P1, SCARA4, SRCL ENSG00000158270 Collectin sub-family member 12 18 316740-500722 Predicted membrane proteins Evidence at protein level HPA047917, HPA071056 Supported Approved Golgi apparatus
Vesicles
Cell Junctions Thyroid cancer:8.10e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 28.2 lung: 16.7 COLQ EAD ENSG00000206561 Collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase 3 15450133-15521751 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA045876 Approved Plasma membrane
Cell Junctions Mixed Tissue enhanced parathyroid gland: 19.2 fallopian tube: 17.4 CRB3 MGC17303 ENSG00000130545 Crumbs family member 3 19 6463777-6467221 Predicted membrane proteins Evidence at protein level HPA013835 Approved Supported Cell Junctions Renal cancer:0.00e+0 (favourable), Urothelial cancer:8.06e-5 (favourable), Endometrial cancer:4.54e-4 (favourable) Mixed Mixed duodenum: 38.4 CTNNA1 CAP102 ENSG00000044115 Catenin (cadherin-associated protein), alpha 1, 102kDa 5 138610967-138935034 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB021089, HPA046119, HPA063535 Approved Validated Plasma membrane
Cell Junctions Renal cancer:7.34e-7 (favourable), Pancreatic cancer:8.02e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 215.4 CTNNBIP1 ICAT, MGC15093 ENSG00000178585 Catenin, beta interacting protein 1 1 9848276-9910336 Predicted intracellular proteins Evidence at protein level HPA042617 Approved Plasma membrane
Cell Junctions
Mitochondria Endometrial cancer:5.68e-6 (favourable) Expressed in all Expressed in all skin: 288.8 CTNND2 GT24, NPRAP ENSG00000169862 Catenin (cadherin-associated protein), delta 2 5 10971840-11904043 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA015077, CAB037339 Supported Approved Nucleoplasm
Golgi apparatus
Cell Junctions Tissue enriched Tissue enriched 18 cerebral cortex: 103.5 spleen: 5.7 CTXN1 FLJ25968 ENSG00000178531 Cortexin 1 19 7924485-7926166 Predicted membrane proteins Evidence at transcript level HPA016669 Uncertain Approved Nucleoplasm
Plasma membrane
Cell Junctions Expressed in all Tissue enhanced cerebral cortex: 100.8 endometrium: 22.7 CXADR CAR ENSG00000154639 Coxsackie virus and adenovirus receptor 21 17512382-17593579 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003342, CAB005103, HPA030411, HPA030412 Supported Validated Plasma membrane
Cell Junctions Head and neck cancer:3.50e-4 (favourable) Expressed in all Mixed skin: 59.6 CYP20A1 CYP-M ENSG00000119004 Cytochrome P450, family 20, subfamily A, polypeptide 1 2 203238449-203305840 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055872, HPA058461 Uncertain Approved Plasma membrane
Cell Junctions
Actin filaments Expressed in all Mixed thyroid gland: 18.7 DCAF13 DKFZP564O0463, Gm83, HSPC064, WDSOF1 ENSG00000164934 DDB1 and CUL4 associated factor 13 8 103414714-103443453 Predicted intracellular proteins Evidence at protein level HPA044504 Uncertain Supported Nucleus
Nucleoli
Cell Junctions
Centrosome
Cytosol Liver cancer:8.05e-6 (unfavourable), Renal cancer:2.85e-4 (unfavourable), Breast cancer:4.06e-4 (unfavourable) Expressed in all Expressed in all testis: 58.5 DCP2 NUDT20 ENSG00000172795 Decapping mRNA 2 5 112976702-113020970 Enzymes, Predicted intracellular proteins Evidence at protein level CAB011677, HPA057676 Approved Approved Nucleoplasm
Cell Junctions
Cytoplasmic bodies Renal cancer:2.66e-5 (unfavourable), Liver cancer:4.84e-4 (unfavourable) Expressed in all Mixed placenta: 18.8 DDB2 DDBB, FLJ34321, UV-DDB2, XPE ENSG00000134574 Damage-specific DNA binding protein 2, 48kDa 11 47214465-47239240 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB025912, HPA058406 Supported Supported Nucleoplasm
Cell Junctions Endometrial cancer:1.20e-4 (favourable), Cervical cancer:1.58e-4 (favourable), Breast cancer:7.29e-4 (favourable) Expressed in all Expressed in all skin: 53.8 DDR1 CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6 ENSG00000204580 Discoidin domain receptor tyrosine kinase 1 6 30876421-30900156 CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010162, CAB025656, HPA057194 Approved Approved Nucleoplasm
Cell Junctions Renal cancer:3.31e-10 (favourable) Expressed in all Mixed cerebral cortex: 51.7 DHRS7B CGI-93, DKFZp566O084, MGC8916, SDR32C1 ENSG00000109016 Dehydrogenase/reductase (SDR family) member 7B 17 21123364-21193265 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012132, HPA016873 Uncertain Approved Plasma membrane
Cell Junctions
Cytosol Endometrial cancer:1.98e-8 (favourable), Renal cancer:3.95e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 49.4 DLG5 KIAA0583, P-dlg ENSG00000151208 Discs, large homolog 5 (Drosophila) 10 77790791-77926526 Predicted intracellular proteins Evidence at protein level HPA001746 Supported Cell Junctions Liver cancer:5.38e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 33.2 DLX1 ENSG00000144355 Distal-less homeobox 1 2 172084740-172089677 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA035666, HPA045884 Approved Approved Nucleus
Vesicles
Cell Junctions Tissue enhanced Tissue enhanced adrenal gland: 1.6;cerebral cortex: 5.0 prostate: 0.7 DNAJC18 MGC29463 ENSG00000170464 DnaJ (Hsp40) homolog, subfamily C, member 18 5 139408588-139444491 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036538, HPA060154 Approved Supported Cell Junctions Pancreatic cancer:5.89e-4 (favourable) Mixed Group enriched 5 cerebral cortex: 30.2;testis: 115.2 ovary: 13.8 DOC2A ENSG00000149927 Double C2-like domains, alpha 16 30005509-30023270 Predicted intracellular proteins Evidence at protein level HPA065676 Uncertain Nucleus
Nucleoli
Cell Junctions Tissue enhanced Group enriched 9 cerebral cortex: 69.9;testis: 21.0 ovary: 5.2 DONSON B17, C21orf60, C2TA, DKFZP434M035 ENSG00000159147 Downstream neighbor of SON 21 33559542-33588708 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039558, HPA049033 Uncertain Approved Nucleoplasm
Cell Junctions
Cytosol Renal cancer:0.00e+0 (unfavourable), Ovarian cancer:2.17e-4 (favourable), Liver cancer:8.22e-4 (unfavourable) Expressed in all Tissue enhanced testis: 40.2 parathyroid gland: 15.4 DPEP1 ENSG00000015413 Dipeptidase 1 (renal) 16 89613308-89638456 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA009426, HPA012783 Supported Approved Nucleus
Cell Junctions Renal cancer:6.84e-4 (favourable) Tissue enriched Tissue enhanced kidney: 262.3;small intestine: 426.5 pancreas: 92.8 DPH1 DPH2L, DPH2L1, OVCA1 ENSG00000108963 Diphthamide biosynthesis 1 17 2030110-2043430 Predicted intracellular proteins Evidence at protein level HPA069750 Approved Nucleoplasm
Cell Junctions Pancreatic cancer:1.78e-5 (favourable) Expressed in all Expressed in all fallopian tube: 30.8 DSC3 CDHF3, DSC, DSC1, DSC2, DSC4 ENSG00000134762 Desmocollin 3 18 30990008-31042815 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB037328, HPA049265, HPA073937 Supported Validated Plasma membrane
Cell Junctions Urothelial cancer:1.04e-5 (unfavourable) Tissue enhanced Group enriched 11 esophagus: 119.5;skin: 455.7 tonsil: 25.9 DSG2 CDHF5 ENSG00000046604 Desmoglein 2 18 31498043-31549008 Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004896, CAB025122 Supported Supported Cell Junctions Renal cancer:3.14e-10 (favourable), Pancreatic cancer:4.94e-5 (unfavourable), Lung cancer:2.43e-4 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable), Colorectal cancer:7.81e-4 (favourable), Cervical cancer:8.22e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 246.8 rectum: 108.5 DSP DPI, DPII, KPPS2, PPKS2 ENSG00000096696 Desmoplakin 6 7541575-7586717 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB037324, HPA045840, HPA054950 Supported Validated Cell Junctions Renal cancer:1.53e-9 (favourable), Urothelial cancer:1.82e-4 (unfavourable) Tissue enhanced Group enriched 8 esophagus: 346.9;skin: 1019.0 placenta: 88.5 DTNA D18S892E, DRP3, DTN, DTN-1, DTN-2, DTN-3 ENSG00000134769 Dystrobrevin, alpha 18 34493290-34891844 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB015196, HPA071177 Supported Approved Nucleoplasm
Cell Junctions
Intermediate filaments Renal cancer:2.64e-7 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 197.7 heart muscle: 100.9 EDA2R EDA-A2R, EDAA2R, TNFRSF27, XEDAR ENSG00000131080 Ectodysplasin A2 receptor X 66595637-66639298 Predicted membrane proteins Evidence at protein level HPA054522 Approved Cell Junctions Mixed Mixed thyroid gland: 9.5 EFCAB11 C14orf143 ENSG00000140025 EF-hand calcium binding domain 11 14 89794669-89954777 Predicted intracellular proteins Evidence at transcript level HPA051209 Approved Cell Junctions
Cytosol Expressed in all Tissue enhanced testis: 59.8 fallopian tube: 17.1 ELMO3 CED-12, CED12, ELMO-3, FLJ13824 ENSG00000102890 Engulfment and cell motility 3 16 67199111-67204029 Predicted intracellular proteins Evidence at protein level HPA021484 Approved Approved Plasma membrane
Cell Junctions Renal cancer:2.77e-5 (favourable) Expressed in all Mixed skin: 39.4 EMC4 FLJ90746, MGC24415, PIG17, TMEM85 ENSG00000128463 ER membrane protein complex subunit 4 15 34224999-34230156 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026868, HPA053440 Approved Approved Cell Junctions
Focal adhesion sites Expressed in all Expressed in all epididymis: 120.7 EPB41 4.1R, EL1 ENSG00000159023 Erythrocyte membrane protein band 4.1 1 28887091-29120046 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA028076, HPA028412, HPA028414 Supported Supported Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.75e-6 (unfavourable), Endometrial cancer:4.58e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable) Expressed in all Expressed in all lymph node: 51.3 EPB41L2 4.1-G ENSG00000079819 Erythrocyte membrane protein band 4.1-like 2 6 130839347-131063322 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005730, HPA006642 Supported Validated Nucleus
Plasma membrane
Cell Junctions Liver cancer:2.41e-5 (unfavourable), Ovarian cancer:2.16e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 139.6 F11R CD321, JAM-1, JAM-A, JAM1, JAMA, JCAM, PAM-1 ENSG00000158769 F11 receptor 1 160995211-161021348 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB004671, HPA043616, HPA061700 Supported Approved Cell Junctions
Microtubules Expressed in all Expressed in all lung: 95.1 FAAP20 C1orf86, FLJ31031 ENSG00000162585 Fanconi anemia core complex associated protein 20 1 2184461-2212720 Predicted intracellular proteins Evidence at protein level HPA038829 Uncertain Supported Nucleoplasm
Nuclear bodies
Cell Junctions Pancreatic cancer:2.88e-4 (favourable), Liver cancer:4.57e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 13.2 FAM126B HYCC2, MGC39518 ENSG00000155744 Family with sequence similarity 126, member B 2 200973718-201071671 Predicted intracellular proteins Evidence at protein level HPA036166, HPA036167, HPA067307 Uncertain Supported Nucleus
Cell Junctions Expressed in all Mixed cerebral cortex: 15.0 FAM13A ARHGAP48, FAM13A1, KIAA0914 ENSG00000138640 Family with sequence similarity 13, member A 4 88725955-89111398 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038108, HPA038109 Uncertain Approved Nucleoli
Cell Junctions
Cytosol Urothelial cancer:4.28e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 113.3 FAM73B C9orf54, FLJ00199, FLJ14596 ENSG00000148343 Family with sequence similarity 73, member B 9 129036621-129072082 Predicted membrane proteins Evidence at protein level HPA041363 Approved Approved Cell Junctions
Cytosol Pancreatic cancer:3.04e-6 (favourable) Expressed in all Mixed small intestine: 15.8 FBLIM1 CAL, FBLP-1, migfilin ENSG00000162458 Filamin binding LIM protein 1 1 15756607-15786594 Predicted intracellular proteins Evidence at protein level HPA025287, HPA072750 Approved Supported Nucleoli fibrillar center
Cell Junctions
Focal adhesion sites Cervical cancer:4.07e-4 (unfavourable), Melanoma:6.15e-4 (unfavourable), Renal cancer:8.64e-4 (unfavourable) Expressed in all Mixed gallbladder: 102.3 FBLN7 FLJ37440, TM14 ENSG00000144152 Fibulin 7 2 112138385-112188216 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA034992 Uncertain Approved Plasma membrane
Cell Junctions Mixed Mixed parathyroid gland: 18.3 FIBCD1 FLJ14810 ENSG00000130720 Fibrinogen C domain containing 1 9 130902438-130939286 Predicted intracellular proteins Evidence at protein level HPA053898, HPA055353 Uncertain Supported Cell Junctions Mixed Tissue enhanced adrenal gland: 4.7;parathyroid gland: 8.5;testis: 5.3 cerebral cortex: 2.5 FIGN ENSG00000182263 Fidgetin 2 163593396-163736012 Predicted intracellular proteins Evidence at protein level HPA034987, HPA057919 Approved Approved Nucleoplasm
Vesicles
Plasma membrane
Cell Junctions
Cytosol Mixed Mixed ovary: 5.1 FLT4 PCL, VEGFR3 ENSG00000037280 Fms-related tyrosine kinase 4 5 180601506-180649624 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000099 Supported Nuclear speckles
Plasma membrane
Cell Junctions Expressed in all Mixed spleen: 18.6 FLVCR1 AXPC1, FLVCR, MFSD7B, PCA ENSG00000162769 Feline leukemia virus subgroup C cellular receptor 1 1 212858255-212899363 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046646 Approved Approved Cell Junctions Renal cancer:1.06e-5 (unfavourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:3.50e-4 (favourable) Expressed in all Tissue enhanced small intestine: 21.9 duodenum: 10.0 FOXA2 HNF3B ENSG00000125798 Forkhead box A2 20 22581005-22585455 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB001388, HPA066846 Approved Supported Nucleoplasm
Cell Junctions Endometrial cancer:7.57e-6 (favourable), Pancreatic cancer:2.34e-4 (favourable), Ovarian cancer:6.28e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 21.3;lung: 20.6;stomach: 31.3 liver: 11.5 FRS2 FRS2A, FRS2alpha, SNT-1, SNT1 ENSG00000166225 Fibroblast growth factor receptor substrate 2 12 69470349-69579789 Predicted intracellular proteins Evidence at protein level HPA038323 Approved Cell Junctions Expressed in all Expressed in all parathyroid gland: 27.0 FZD2 ENSG00000180340 Frizzled class receptor 2 17 44557459-44559570 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA057667 Uncertain Approved Nuclear bodies
Cell Junctions Expressed in all Mixed placenta: 4.9 GABRA5 ENSG00000186297 Gamma-aminobutyric acid (GABA) A receptor, alpha 5 15 26866363-26949207 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA077031 Supported Cell Junctions Mixed Tissue enriched 43 cerebral cortex: 82.0 esophagus: 1.8 GAS2L1 GAR22 ENSG00000185340 Growth arrest-specific 2 like 1 22 29306582-29312785 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019858 Approved Approved Plasma membrane
Cell Junctions Renal cancer:8.44e-4 (favourable) Expressed in all Expressed in all testis: 32.2 GID8 bA305P22.1, C20orf11, FLJ20602, TWA1 ENSG00000101193 GID complex subunit 8 20 62938119-62948475 Predicted intracellular proteins Evidence at protein level HPA049929, HPA055047 Approved Supported Nucleoplasm
Cell Junctions Renal cancer:3.22e-4 (favourable), Endometrial cancer:4.78e-4 (unfavourable) Expressed in all Expressed in all skin: 32.5 GIPC1 C19orf3, GIPC, GLUT1CBP, Hs.6454, NIP, RGS19IP1, SEMCAP, SYNECTIN, TIP-2 ENSG00000123159 GIPC PDZ domain containing family, member 1 19 14477760-14496149 Predicted intracellular proteins Evidence at protein level HPA043958, HPA061786 Approved Approved Nucleus
Plasma membrane
Cell Junctions Expressed in all Expressed in all esophagus: 104.4 GJB3 CX31, DFNA2, EKV ENSG00000188910 Gap junction protein, beta 3, 31kDa 1 34781189-34786369 Disease related genes, Predicted membrane proteins Evidence at protein level HPA074472 Supported Vesicles
Cell Junctions Pancreatic cancer:7.56e-5 (unfavourable), Lung cancer:4.56e-4 (unfavourable) Mixed Tissue enhanced esophagus: 33.7;skin: 77.4 tonsil: 12.1 GJB4 CX30.3 ENSG00000189433 Gap junction protein, beta 4, 30.3kDa 1 34759741-34763724 Disease related genes, Predicted membrane proteins Evidence at protein level HPA055112 Supported Cell Junctions Pancreatic cancer:3.24e-5 (unfavourable), Cervical cancer:5.48e-4 (favourable) Group enriched Tissue enriched 5 skin: 27.8 epididymis: 5.0 GJB6 CX30, DFNA3, ED2, EDH, HED ENSG00000121742 Gap junction protein, beta 6, 30kDa 13 20221971-20232395 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014846 Supported Cell Junctions Tissue enhanced Group enriched 5 bone marrow: 47.6;cerebral cortex: 39.6;esophagus: 150.3;skin: 32.0 tonsil: 12.7 GJC1 CX45, GJA7 ENSG00000182963 Gap junction protein, gamma 1, 45kDa 17 44798448-44830816 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA071788 Uncertain Nucleoli
Cell Junctions
Cytosol Renal cancer:3.55e-8 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 43.9;placenta: 50.9;smooth muscle: 48.2 seminal vesicle: 27.0 GPATCH1 ECGP, FLJ10206, FLJ38686, GPATC1 ENSG00000076650 G patch domain containing 1 19 33080880-33130542 Predicted intracellular proteins Evidence at protein level HPA043430, HPA043604 Approved Uncertain Nucleoplasm
Plasma membrane
Cell Junctions Endometrial cancer:8.20e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 8.5 GPR142 PGR2 ENSG00000257008 G protein-coupled receptor 142 17 74367407-74372622 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA031392 Uncertain Uncertain Plasma membrane
Cell Junctions
Cytosol Tissue enhanced Not detected appendix: 0.1 GPR157 FLJ12132 ENSG00000180758 G protein-coupled receptor 157 1 9100305-9129170 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA028697 Uncertain Uncertain Nucleoli
Plasma membrane
Cell Junctions Expressed in all Mixed parathyroid gland: 23.9 GTF2F1 BTF4, RAP74, TF2F1, TFIIF ENSG00000125651 General transcription factor IIF, polypeptide 1, 74kDa 19 6379569-6393981 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA022793, HPA028707 Approved Validated Nucleus
Cell Junctions Endometrial cancer:8.39e-4 (favourable), Renal cancer:9.80e-4 (favourable) Expressed in all Expressed in all ovary: 93.6 HCAR2 GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG ENSG00000182782 Hydroxycarboxylic acid receptor 2 12 122701293-122703343 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028660 Approved Approved Cell Junctions Group enriched Tissue enhanced spleen: 36.5 esophagus: 25.6 HCAR3 GPR109B, HCA3, HM74 ENSG00000255398 Hydroxycarboxylic acid receptor 3 12 122714756-122716892 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028660 Approved Approved Cell Junctions Mixed Tissue enhanced bone marrow: 16.7;spleen: 22.1 appendix: 12.6 HINFP DKFZP434F162, HiNF-P, MIZF, ZNF743 ENSG00000172273 Histone H4 transcription factor 11 119121587-119136044 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA059053, HPA061008 Uncertain Supported Nucleus
Cell Junctions
Cytosol Liver cancer:4.44e-8 (unfavourable), Thyroid cancer:5.26e-4 (favourable) Expressed in all Expressed in all testis: 12.0 HLA-DPB1 HLA-DP1B ENSG00000223865 Major histocompatibility complex, class II, DP beta 1 6 33075926-33087201 Predicted membrane proteins Evidence at protein level HPA011078, HPA058509 Approved Approved Nucleus
Cell Junctions Endometrial cancer:3.38e-4 (favourable) Expressed in all Expressed in all spleen: 174.2 HOXD4 HOX4, HOX4B ENSG00000170166 Homeobox D4 2 176151222-176153226 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA054383, HPA070349 Approved Validated Nucleus
Cell Junctions Tissue enhanced Tissue enhanced endometrium: 23.5;epididymis: 22.6 fallopian tube: 15.4 IGSF11 BT-IgSF, CT119, Igsf13, MGC35227, VSIG3 ENSG00000144847 Immunoglobulin superfamily, member 11 3 118900557-119146068 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA046377 Uncertain Approved Nucleus
Cell Junctions
Cytosol Group enriched Tissue enhanced cerebral cortex: 31.1;testis: 64.7 ovary: 20.0 IGSF23 ENSG00000216588 Immunoglobulin superfamily, member 23 19 44613630-44636781 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA051811, HPA054591 Uncertain Approved Nucleus
Cell Junctions Liver cancer:7.20e-6 (favourable) Tissue enriched Group enriched 7 duodenum: 15.6;liver: 13.1;small intestine: 17.8 testis: 2.3 ILK ENSG00000166333 Integrin-linked kinase 11 6603708-6610874 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004041, HPA048437 Supported Validated Cell Junctions
Focal adhesion sites Renal cancer:2.44e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 554.5 INADL Cipp, PATJ ENSG00000132849 InaD-like (Drosophila) 1 61742477-62178675 Predicted intracellular proteins Evidence at protein level HPA066352, HPA066960, HPA069079 Approved Supported Cell Junctions
Microtubule organizing center
Cytosol Renal cancer:1.47e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 35.2 IQGAP1 HUMORFA01, KIAA0051, p195, SAR1 ENSG00000140575 IQ motif containing GTPase activating protein 1 15 90388218-90502243 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013302, HPA014055 Supported Supported Plasma membrane
Cell Junctions Pancreatic cancer:5.67e-5 (unfavourable) Expressed in all Expressed in all endometrium: 119.6 IREB2 IRP2 ENSG00000136381 Iron-responsive element binding protein 2 15 78437431-78501456 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB032885, HPA040371, HPA068982 Uncertain Approved Cell Junctions
Cytosol Expressed in all Expressed in all thyroid gland: 47.9 ITGA2B CD41, CD41B, GP2B, PPP1R93 ENSG00000005961 Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) 17 44372180-44389505 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018611, HPA031168, HPA031169, HPA031170, HPA031171 Supported Uncertain Nucleoplasm
Cell Junctions
Cytosol Mixed Tissue enhanced bone marrow: 11.2;epididymis: 28.6 testis: 4.4 ITGB4 CD104 ENSG00000132470 Integrin, beta 4 17 75721328-75757818 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002422, CAB005258, HPA036348, HPA036349 Supported Supported Nucleus
Plasma membrane
Cell Junctions Pancreatic cancer:6.39e-4 (unfavourable), Lung cancer:7.18e-4 (unfavourable) Expressed in all Mixed skin: 84.4 ITGB6 ENSG00000115221 Integrin, beta 6 2 160099666-160271888 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA023626, CAB073536 Approved Uncertain Nucleoplasm
Cell Junctions
Centrosome Pancreatic cancer:5.03e-6 (unfavourable) Mixed Tissue enhanced lung: 66.9 urinary bladder: 31.3 JUP CTNNG, DP3, DPIII, PDGB, PKGB ENSG00000173801 Junction plakoglobin 17 41754604-41786931 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002139, HPA032047 Supported Validated Vesicles
Plasma membrane
Cell Junctions Renal cancer:2.06e-10 (favourable) Expressed in all Group enriched 6 esophagus: 493.6;skin: 787.3 fallopian tube: 112.6 KCNK13 K2p13.1, THIK-1, THIK1 ENSG00000152315 Potassium channel, two pore domain subfamily K, member 13 14 90061765-90185857 Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level HPA003514 Approved Approved Nuclear speckles
Cell Junctions Mixed Tissue enhanced parathyroid gland: 14.3;testis: 14.4 kidney: 3.3 KDF1 C1orf172, FLJ34633, RP11-344H11.3 ENSG00000175707 Keratinocyte differentiation factor 1 1 26949562-26960406 Predicted intracellular proteins Evidence at protein level HPA028639, HPA068312 Uncertain Supported Nucleoplasm
Cell Junctions
Mitotic spindle Renal cancer:3.04e-13 (favourable), Urothelial cancer:4.40e-4 (favourable) Mixed Mixed epididymis: 23.7 KIAA0895 ENSG00000164542 KIAA0895 7 36324221-36390125 Predicted intracellular proteins Evidence at transcript level HPA020512, HPA021036, HPA061066 Uncertain Approved Nucleus
Plasma membrane
Cell Junctions
Cytosol Expressed in all Tissue enhanced testis: 43.8 parathyroid gland: 23.4 KIAA1462 JCAD ENSG00000165757 KIAA1462 10 30012800-30115494 Predicted intracellular proteins Evidence at protein level HPA017956 Approved Supported Vesicles
Cell Junctions Stomach cancer:2.01e-4 (unfavourable), Renal cancer:2.54e-4 (unfavourable) Expressed in all Mixed placenta: 48.3 KIAA1522 ENSG00000162522 KIAA1522 1 32741885-32774970 Predicted intracellular proteins Evidence at protein level HPA032050, HPA032051, HPA064839 Approved Supported Nucleoplasm
Plasma membrane
Cell Junctions Liver cancer:6.29e-7 (unfavourable), Renal cancer:1.29e-5 (favourable), Pancreatic cancer:8.25e-5 (unfavourable) Expressed in all Mixed skin: 73.0 LDLRAD3 LRAD3 ENSG00000179241 Low density lipoprotein receptor class A domain containing 3 11 35943981-36232136 Predicted membrane proteins Evidence at protein level HPA038251 Approved Supported Cell Junctions Renal cancer:5.05e-8 (unfavourable), Lung cancer:9.34e-6 (unfavourable), Urothelial cancer:2.14e-5 (unfavourable), Cervical cancer:2.24e-4 (unfavourable) Expressed in all Mixed breast: 22.9 LMCD1 ENSG00000071282 LIM and cysteine-rich domains 1 3 8501707-8574673 Predicted intracellular proteins Evidence at protein level HPA024059 Approved Supported Nucleus
Plasma membrane
Cell Junctions
Cytosol Renal cancer:8.66e-5 (unfavourable) Expressed in all Mixed skeletal muscle: 201.9 LMTK3 KIAA1883, LMR3, PPP1R101, TYKLM3 ENSG00000142235 Lemur tyrosine kinase 3 19 48485271-48513189 Enzymes, Predicted membrane proteins Evidence at protein level HPA040203 Approved Nucleoplasm
Cell Junctions Renal cancer:3.18e-8 (favourable) Mixed Group enriched 5 cerebral cortex: 20.4;parathyroid gland: 4.8 duodenum: 2.3 LNX1 LNX, MPDZ, PDZRN2 ENSG00000072201 Ligand of numb-protein X 1, E3 ubiquitin protein ligase 4 53459301-53701405 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002235, HPA071091 Approved Supported Cell Junctions
Cytosol Renal cancer:3.08e-7 (favourable) Expressed in all Mixed placenta: 41.1 LRRC34 MGC27085 ENSG00000171757 Leucine rich repeat containing 34 3 169793428-169812986 Predicted intracellular proteins Evidence at protein level HPA035747, HPA058105 Approved Approved Cell Junctions
Microtubules
Cytokinetic bridge Mixed Group enriched 8 fallopian tube: 12.2;testis: 26.8 cerebral cortex,thyroid gland: 2.3 MACF1 ABP620, ACF7, FLJ45612, FLJ46776, KIAA0465, KIAA1251, MACF ENSG00000127603 Microtubule-actin crosslinking factor 1 1 39081316-39487177 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013713, HPA068064, HPA068103 Approved Supported Plasma membrane
Cell Junctions
Actin filaments Renal cancer:2.77e-5 (favourable) Expressed in all Expressed in all lung: 137.3 MAGI1 AIP3, BAIAP1, BAP1, MAGI-1, TNRC19, WWP3 ENSG00000151276 Membrane associated guanylate kinase, WW and PDZ domain containing 1 3 65353525-66038834 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031851, HPA031852, HPA031853 Approved Validated Nucleoplasm
Cell Junctions Renal cancer:4.55e-8 (favourable) Expressed in all Mixed thyroid gland: 18.8 MAGI3 MAGI-3 ENSG00000081026 Membrane associated guanylate kinase, WW and PDZ domain containing 3 1 113390749-113685923 Predicted intracellular proteins Evidence at protein level HPA007923, HPA008444 Approved Supported Cell Junctions Renal cancer:2.60e-8 (favourable), Ovarian cancer:4.29e-4 (favourable) Expressed in all Mixed lung: 20.9 MAP2K4 JNKK1, MEK4, MKK4, PRKMK4, SERK1 ENSG00000065559 Mitogen-activated protein kinase kinase 4 17 12020824-12143830 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007751, HPA060074 Supported Approved Nucleoplasm
Cell Junctions Expressed in all Expressed in all cerebral cortex: 64.2 MAP3K12 DLK, MEKK12, MUK, ZPK, ZPKP1 ENSG00000139625 Mitogen-activated protein kinase kinase kinase 12 12 53479669-53500063 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039936, HPA071996 Approved Approved Nucleus
Cell Junctions Renal cancer:5.43e-10 (unfavourable), Pancreatic cancer:1.51e-4 (favourable) Mixed Mixed gallbladder: 24.0 MAPK15 ERK7, ERK8 ENSG00000181085 Mitogen-activated protein kinase 15 8 143716259-143722458 Enzymes, Predicted intracellular proteins Evidence at protein level HPA002704 Approved Nucleoplasm
Cell Junctions
Cytosol Mixed Tissue enhanced fallopian tube: 43.3 parathyroid gland: 13.2 MARVELD2 DFNB49, FLJ30532, MRVLDC2, TRIC ENSG00000152939 MARVEL domain containing 2 5 69415112-69444330 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018119, HPA061726 Uncertain Supported Cell Junctions Renal cancer:2.84e-13 (favourable) Mixed Tissue enhanced thyroid gland: 19.7 small intestine: 8.9 MEPCE BCDIN3, FLJ20257, MePCE ENSG00000146834 Methylphosphate capping enzyme 7 100428790-100434126 Predicted intracellular proteins Evidence at protein level CAB026384, HPA051587 Supported Approved Nucleoplasm
Cell Junctions Renal cancer:1.01e-10 (favourable), Endometrial cancer:6.01e-6 (unfavourable) Expressed in all Expressed in all testis: 87.7 METTL9 DREV1 ENSG00000197006 Methyltransferase like 9 16 21597218-21657473 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA053588, HPA056347 Uncertain Approved Nucleus
Cell Junctions
Cytosol Liver cancer:8.71e-4 (unfavourable) Expressed in all Expressed in all kidney: 182.7 MICALL1 KIAA1668, MICAL-L1, MIRAB13 ENSG00000100139 MICAL-like 1 22 37905657-37942822 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043480, HPA051956 Uncertain Supported Cell Junctions
Microtubule organizing center
Cytosol Liver cancer:3.08e-6 (unfavourable) Expressed in all Expressed in all smooth muscle: 50.6 MLLT4 AF-6, AF6 ENSG00000130396 Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 4 6 167826922-167972023 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868 Approved Validated Nucleoplasm
Plasma membrane
Cell Junctions Breast cancer:7.43e-5 (unfavourable) Expressed in all Expressed in all esophagus: 111.1 MLST8 GbetaL, GBL, Lst8, Pop3 ENSG00000167965 MTOR associated protein, LST8 homolog 16 2204248-2209416 Predicted intracellular proteins Evidence at protein level CAB019935, HPA041841 Approved Approved Nucleoplasm
Golgi apparatus
Cell Junctions Renal cancer:7.60e-4 (favourable) Expressed in all Expressed in all testis: 28.7 MOAP1 MAP-1, PNMA4 ENSG00000165943 Modulator of apoptosis 1 14 93182196-93184928 Predicted intracellular proteins Evidence at protein level HPA000939 Uncertain Approved Nucleus
Cell Junctions Lung cancer:7.37e-9 (favourable), Renal cancer:3.15e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 86.4 MPP7 FLJ32798 ENSG00000150054 Membrane protein, palmitoylated 7 (MAGUK p55 subfamily member 7) 10 28050993-28334486 Predicted intracellular proteins Evidence at protein level HPA037597, HPA037598 Supported Supported Cell Junctions Renal cancer:2.79e-14 (favourable), Lung cancer:5.88e-4 (favourable) Mixed Mixed esophagus: 41.3 MPZL2 EVA, EVA1 ENSG00000149573 Myelin protein zero-like 2 11 118253403-118264536 Predicted membrane proteins Evidence at protein level HPA051395, HPA060740 Approved Approved Cell Junctions Pancreatic cancer:1.14e-4 (unfavourable), Thyroid cancer:1.62e-4 (favourable) Expressed in all Tissue enhanced esophagus: 210.0 urinary bladder: 122.3 MRPL46 C15orf4, LIECG2, P2ECSL ENSG00000259494 Mitochondrial ribosomal protein L46 15 88459476-88467419 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA050166 Uncertain Supported Nucleoplasm
Cell Junctions
Mitochondria Renal cancer:2.09e-6 (favourable) Expressed in all Expressed in all adrenal gland: 50.5 MRPS18B C6orf14, HSPC183, MRPS18-2, PTD017 ENSG00000204568 Mitochondrial ribosomal protein S18B 6 30617709-30626395 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA043485, HPA050334 Supported Supported Cell Junctions
Mitochondria Renal cancer:3.99e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 13.2 MTFR1L FAM54B ENSG00000117640 Mitochondrial fission regulator 1-like 1 25818640-25832942 Predicted intracellular proteins Evidence at protein level HPA027124, HPA027130 Approved Approved Cell Junctions
Mitochondria Renal cancer:5.89e-12 (favourable), Endometrial cancer:6.81e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 155.3 MTHFR ENSG00000177000 Methylenetetrahydrofolate reductase (NAD(P)H) 1 11785723-11806920 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA063389 Approved Cell Junctions Head and neck cancer:3.97e-5 (favourable), Pancreatic cancer:4.81e-5 (favourable), Liver cancer:1.19e-4 (unfavourable), Renal cancer:2.12e-4 (favourable) Expressed in all Expressed in all epididymis: 65.3 MVD MPD ENSG00000167508 Mevalonate (diphospho) decarboxylase 16 88651935-88663161 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041404, HPA048250 Uncertain Approved Cell Junctions
Cytosol Endometrial cancer:2.17e-4 (favourable) Expressed in all Expressed in all duodenum: 34.8 NAMPT PBEF, PBEF1 ENSG00000105835 Nicotinamide phosphoribosyltransferase 7 106248285-106286326 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB034349, HPA047776, HPA057722 Approved Approved Nuclear speckles
Cell Junctions Renal cancer:2.49e-6 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable), Cervical cancer:4.78e-4 (unfavourable), Head and neck cancer:8.81e-4 (unfavourable) Expressed in all Expressed in all appendix: 792.4 NEU1 NEU ENSG00000204386 Sialidase 1 (lysosomal sialidase) 6 31857659-31862906 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA015634, HPA021506 Approved Supported Vesicles
Cell Junctions Expressed in all Mixed thyroid gland: 14.3 NHS ENSG00000188158 Nance-Horan syndrome (congenital cataracts and dental anomalies) X 17375420-17735994 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031497, HPA076257 Uncertain Supported Cell Junctions Endometrial cancer:1.68e-4 (favourable) Mixed Mixed endometrium: 7.8 NLK ENSG00000087095 Nemo-like kinase 17 28041737-28196381 Enzymes, Predicted intracellular proteins Evidence at protein level HPA018192, HPA056511 Approved Supported Nucleus
Nucleoli
Cell Junctions Expressed in all Expressed in all cerebral cortex: 52.5 NLRX1 CLR11.3, NOD9 ENSG00000160703 NLR family member X1 11 119166568-119184016 Predicted intracellular proteins Evidence at protein level HPA061516 Supported Supported Plasma membrane
Cell Junctions
Mitochondria Renal cancer:2.59e-6 (favourable), Endometrial cancer:2.47e-5 (favourable) Expressed in all Expressed in all esophagus: 37.9 NPNT EGFL6L, POEM ENSG00000168743 Nephronectin 4 105894775-106004027 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA003711, HPA050203 Supported Approved Nucleus
Cell Junctions
Cytosol Renal cancer:8.28e-8 (favourable) Expressed in all Tissue enhanced lung: 168.7;thyroid gland: 274.6 prostate: 126.2 NR2C1 TR2, TR2-11 ENSG00000120798 Nuclear receptor subfamily 2, group C, member 1 12 95020229-95073703 Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA035040, HPA035041, HPA067767 Supported Supported Nucleus
Cell Junctions
Cytosol Renal cancer:1.03e-6 (unfavourable), Liver cancer:5.18e-5 (unfavourable), Urothelial cancer:5.62e-5 (favourable) Expressed in all Mixed testis: 21.8 NUDT9 MGC3037 ENSG00000170502 Nudix (nucleoside diphosphate linked moiety X)-type motif 9 4 87422582-87459454 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA036917, HPA044866, HPA078535 Approved Supported Nuclear membrane
Cell Junctions
Mitochondria Renal cancer:8.00e-11 (favourable), Endometrial cancer:7.43e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 84.9 NUMB C14orf41 ENSG00000133961 Numb homolog (Drosophila) 14 73275107-73463642 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB011478 Approved Approved Cell Junctions
Cytosol Renal cancer:2.32e-6 (favourable) Expressed in all Expressed in all lung: 78.1 OCLN PPP1R115 ENSG00000197822 Occludin 5 69492292-69558104 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA005933, CAB013075, CAB068212, CAB068213, CAB068214 Supported Supported Plasma membrane
Cell Junctions Renal cancer:6.59e-11 (favourable) Mixed Tissue enhanced thyroid gland: 78.3 lung: 39.9 PAK4 ENSG00000130669 P21 protein (Cdc42/Rac)-activated kinase 4 19 39125770-39182816 Enzymes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB025747, CAB044670, HPA070175, HPA072220 Uncertain Supported Plasma membrane
Cell Junctions Renal cancer:5.29e-5 (favourable), Prostate cancer:9.85e-4 (unfavourable) Expressed in all Expressed in all prostate: 42.2 PAK6 PAK5 ENSG00000137843 P21 protein (Cdc42/Rac)-activated kinase 6 15 40238759-40277487 Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA031124 Approved Approved Nucleus
Nucleoli fibrillar center
Cell Junctions Not detected Mixed cerebral cortex: 28.7 PAK6 ENSG00000259288 P21 protein (Cdc42/Rac)-activated kinase 6 15 40217428-40276396 Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA031124 Uncertain Approved Nucleus
Nucleoli fibrillar center
Cell Junctions Not detected Not detected cerebral cortex: 0.1 PARD3 ASIP, Baz, Bazooka, PAR3, PARD3A, PPP1R118 ENSG00000148498 Par-3 family cell polarity regulator 10 34109560-34815325 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030443 Approved Validated Cell Junctions Liver cancer:1.73e-5 (unfavourable), Urothelial cancer:4.41e-4 (unfavourable) Expressed in all Mixed skin: 68.8 PARD3B ALS2CR19, PAR3beta, Par3L ENSG00000116117 Par-3 family cell polarity regulator beta 2 204545793-205620162 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035283 Approved Supported Cell Junctions Renal cancer:2.67e-10 (favourable) Expressed in all Mixed parathyroid gland: 13.1 PARD6A PAR-6, PAR-6A, PAR6alpha, TAX40, TIP-40 ENSG00000102981 Par-6 family cell polarity regulator alpha 16 67660946-67662778 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009733, HPA041551 Approved Supported Cell Junctions
Actin filaments
Cytosol Renal cancer:3.08e-7 (favourable), Breast cancer:5.40e-4 (favourable) Expressed in all Tissue enhanced testis: 20.0 cerebral cortex: 12.1 PCDH1 pc42 ENSG00000156453 Protocadherin 1 5 141853111-141879246 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047720, HPA050538 Approved Approved Nucleus
Nucleoli
Cell Junctions Liver cancer:4.96e-5 (unfavourable), Renal cancer:7.55e-5 (favourable), Pancreatic cancer:3.61e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 40.4 PCDH7 BH-Pcdh, PPP1R120 ENSG00000169851 Protocadherin 7 4 30720415-31146805 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011866, HPA046521 Uncertain Validated Plasma membrane
Cell Junctions Lung cancer:6.46e-5 (unfavourable), Stomach cancer:6.42e-4 (unfavourable) Mixed Mixed cerebral cortex: 46.1 PCDHA11 CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11 ENSG00000249158 Protocadherin alpha 11 5 140868183-141012344 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA077160 Approved Vesicles
Cell Junctions Not detected Tissue enhanced cerebral cortex: 7.6;parathyroid gland: 4.7 testis: 2.3 PCDHGA7 PCDH-GAMMA-A7 ENSG00000253537 Protocadherin gamma subfamily A, 7 5 141382739-141512979 Predicted membrane proteins Evidence at transcript level HPA008755, HPA077995 Uncertain Uncertain Plasma membrane
Cell Junctions Mixed Tissue enhanced cerebral cortex: 7.4 thyroid gland: 3.2 PDGFRA CD140a, GAS9, PDGFR2 ENSG00000134853 Platelet-derived growth factor receptor, alpha polypeptide 4 54229097-54298247 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA004947, CAB018143 Supported Supported Nucleus
Plasma membrane
Cell Junctions Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable) Expressed in all Expressed in all ovary: 222.0 PDLIM1 CLIM1, CLP-36, CLP36, hCLIM1 ENSG00000107438 PDZ and LIM domain 1 10 95237572-95291024 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017010, CAB072838, CAB072840 Approved Supported Plasma membrane
Cell Junctions
Actin filaments Endometrial cancer:1.14e-5 (favourable) Expressed in all Expressed in all small intestine: 278.6 PEAR1 FLJ00193, JEDI, MEGF12 ENSG00000187800 Platelet endothelial aggregation receptor 1 1 156893698-156916434 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035217 Approved Approved Nucleoplasm
Cell Junctions
Centrosome Renal cancer:4.31e-4 (unfavourable) Expressed in all Mixed placenta: 16.8 PGLYRP2 PGLYRPL, PGRP-L, PGRPL, tagL, tagL-alpha, tagl-beta, TAGL-like ENSG00000161031 Peptidoglycan recognition protein 2 19 15468645-15498956 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB033468, HPA043568, HPA046311, HPA075237 Approved Approved Cell Junctions Tissue enriched Tissue enriched 17 liver: 132.5 testis: 7.8 PGS1 DKFZP762M186 ENSG00000087157 Phosphatidylglycerophosphate synthase 1 17 78378640-78425114 Enzymes, Predicted intracellular proteins Evidence at protein level HPA022526 Approved Approved Vesicles
Cell Junctions
Intermediate filaments Renal cancer:1.16e-5 (unfavourable), Pancreatic cancer:7.33e-5 (favourable), Liver cancer:1.37e-4 (unfavourable), Prostate cancer:9.94e-4 (unfavourable) Expressed in all Expressed in all placenta: 26.5 PKP2 ENSG00000057294 Plakophilin 2 12 32790745-32896840 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA014314, HPA056908 Approved Validated Nucleoplasm
Cell Junctions Lung cancer:6.79e-4 (unfavourable), Colorectal cancer:8.55e-4 (favourable) Mixed Tissue enhanced fallopian tube: 113.1;heart muscle: 114.5 parathyroid gland: 50.2 PKP3 ENSG00000184363 Plakophilin 3 11 392614-404908 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB012993, HPA062937 Supported Validated Nucleoplasm
Cell Junctions
Cytosol Lung cancer:2.89e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable), Pancreatic cancer:3.93e-4 (unfavourable) Mixed Tissue enhanced esophagus: 98.6;skin: 148.5 duodenum: 32.2 PKP4 p0071 ENSG00000144283 Plakophilin 4 2 158456964-158682879 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB037334, HPA066647, HPA070648 Approved Validated Plasma membrane
Cell Junctions Renal cancer:3.29e-7 (favourable), Endometrial cancer:5.80e-4 (favourable) Expressed in all Expressed in all kidney: 65.1 PLEKHA6 KIAA0969, PEPP3 ENSG00000143850 Pleckstrin homology domain containing, family A member 6 1 204218851-204377665 Predicted intracellular proteins Evidence at protein level HPA028152, HPA054311 Approved Supported Vesicles
Cell Junctions
Microtubule organizing center Urothelial cancer:3.57e-4 (favourable) Expressed in all Mixed stomach: 26.7 PLEKHA7 DKFZp686M22243 ENSG00000166689 Pleckstrin homology domain containing, family A member 7 11 16778295-17014443 Predicted intracellular proteins Evidence at protein level HPA038610 Approved Supported Cell Junctions
Cytosol Renal cancer:1.89e-15 (favourable) Mixed Mixed parathyroid gland: 38.8 PLEKHG4 ARHGEF44, DKFZP434I216, SCA4 ENSG00000196155 Pleckstrin homology domain containing, family G (with RhoGef domain) member 4 16 67277510-67289499 Predicted intracellular proteins Evidence at protein level HPA055696 Approved Cell Junctions Renal cancer:6.72e-9 (unfavourable) Expressed in all Tissue enhanced testis: 41.3 ovary: 18.7 PLXNA3 6.3, Plxn3, PLXN4, SEX, XAP-6 ENSG00000130827 Plexin A3 X 154458281-154477779 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA058989 Supported Vesicles
Plasma membrane
Cell Junctions Expressed in all Mixed skin: 12.1 PROM2 ENSG00000155066 Prominin 2 2 95274453-95291308 Predicted membrane proteins Evidence at protein level CAB046005, HPA063728 Supported Approved Nucleoplasm
Plasma membrane
Cell Junctions Renal cancer:1.55e-6 (unfavourable), Breast cancer:2.16e-4 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable) Mixed Tissue enhanced skin: 71.3 esophagus: 44.8 PRR15 ENSG00000176532 Proline rich 15 7 29563811-29567295 Predicted intracellular proteins Evidence at protein level HPA040996, HPA048121 Supported Uncertain Vesicles
Cell Junctions Renal cancer:1.83e-6 (favourable), Endometrial cancer:6.37e-4 (favourable), Lung cancer:7.23e-4 (unfavourable) Mixed Tissue enhanced cervix, uterine: 91.8 colon,small intestine: 80.6 PSEN1 AD3, FAD, PS1, S182 ENSG00000080815 Presenilin 1 14 73136418-73223691 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB006844, HPA030760, HPA067496 Approved Approved Nucleus
Golgi apparatus
Cell Junctions Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 66.1 PTPRB PTPB ENSG00000127329 Protein tyrosine phosphatase, receptor type, B 12 70515866-70637440 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004782, HPA067868 Uncertain Approved Vesicles
Plasma membrane
Cell Junctions Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable) Expressed in all Mixed lung: 54.1 PTPRK R-PTP-kappa ENSG00000152894 Protein tyrosine phosphatase, receptor type, K 6 127968779-128520674 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054056, HPA054822 Uncertain Supported Vesicles
Plasma membrane
Cell Junctions Renal cancer:9.33e-5 (favourable), Pancreatic cancer:1.99e-4 (unfavourable) Expressed in all Mixed gallbladder: 27.9 PTPRR EC-PTP, PCPTP1, PTP-SL, PTPBR7, PTPRQ ENSG00000153233 Protein tyrosine phosphatase, receptor type, R 12 70638073-70920843 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB011461, HPA011851, HPA071067 Uncertain Supported Plasma membrane
Cell Junctions
Cytosol Urothelial cancer:1.40e-5 (favourable) Mixed Tissue enhanced cerebral cortex: 20.9 endometrium: 8.9 PVALB D22S749 ENSG00000100362 Parvalbumin 22 36800684-36819479 Predicted intracellular proteins Evidence at protein level CAB002515, HPA048536 Supported Approved Nucleoplasm
Nucleoli
Cell Junctions Group enriched Tissue enriched 12 parathyroid gland: 536.6 kidney: 43.1 PVRL2 CD112, HVEB, PRR2, PVRR2 ENSG00000130202 Poliovirus receptor-related 2 (herpesvirus entry mediator B) 19 44846175-44889228 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012759, CAB026138, HPA073459 Supported Uncertain Nucleoli fibrillar center
Cell Junctions Expressed in all Expressed in all placenta: 111.0 PYM1 PYM, WIBG ENSG00000170473 PYM homolog 1, exon junction complex associated factor 12 55901413-55932618 Predicted intracellular proteins Evidence at protein level CAB012803, HPA039717, HPA046200 Supported Supported Nucleus
Nucleoli
Cell Junctions
Cytosol Urothelial cancer:1.34e-4 (favourable), Liver cancer:3.05e-4 (unfavourable) Expressed in all Expressed in all esophagus: 50.5 RAB25 CATX-8 ENSG00000132698 RAB25, member RAS oncogene family 1 156061160-156070514 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA010872, CAB033645 Approved Uncertain Cell Junctions
Cytosol Renal cancer:1.38e-6 (favourable) Mixed Tissue enhanced esophagus: 298.6 skin: 169.3 RAD51C FANCO, RAD51L2 ENSG00000108384 RAD51 paralog C 17 58692573-58735611 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA045198 Supported Nucleus
Vesicles
Cell Junctions
Mitochondria
Cytosol Liver cancer:8.68e-5 (unfavourable), Pancreatic cancer:5.33e-4 (favourable) Expressed in all Expressed in all testis: 37.1 RASA4B ENSG00000170667 RAS p21 protein activator 4B 7 102482445-102517781 Predicted intracellular proteins, RAS pathway related proteins Evidence at transcript level HPA043010 Uncertain Uncertain Vesicles
Cell Junctions Not detected Tissue enhanced skeletal muscle: 39.7 cerebral cortex: 15.7 RASAL1 RASAL ENSG00000111344 RAS protein activator like 1 (GAP1 like) 12 113098819-113136239 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA041650 Uncertain Approved Plasma membrane
Cell Junctions
Cytosol Endometrial cancer:3.26e-5 (unfavourable) Mixed Tissue enriched 6 parathyroid gland: 116.7 cerebral cortex: 19.5 RASSF4 AD037, MGC44914 ENSG00000107551 Ras association (RalGDS/AF-6) domain family member 4 10 44959407-44995891 Predicted intracellular proteins Evidence at protein level HPA038834 Approved Approved Nucleus
Nucleoli
Cell Junctions Expressed in all Expressed in all cerebral cortex: 71.6 RPUSD1 C16orf40, MGC19600, RLUCL ENSG00000007376 RNA pseudouridylate synthase domain containing 1 16 784974-788397 Predicted intracellular proteins Evidence at protein level HPA041144, HPA041938 Approved Approved Nucleus
Golgi apparatus
Cell Junctions
Cytosol Expressed in all Expressed in all appendix: 13.4 RRP7A CGI-96 ENSG00000189306 Ribosomal RNA processing 7 homolog A 22 42509968-42519802 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001586, HPA046768 Approved Approved Nucleus
Nucleoli
Cell Junctions Liver cancer:1.21e-5 (unfavourable) Expressed in all Expressed in all epididymis: 49.0 RSC1A1 RS1 ENSG00000215695 Regulatory solute carrier protein, family 1, member 1 1 15659869-15661722 Predicted intracellular proteins Evidence at protein level HPA027813, HPA028676 Approved Supported Nucleoplasm
Cell Junctions Not detected Mixed smooth muscle: 5.2 S100A14 BCMP84, S100A15 ENSG00000189334 S100 calcium binding protein A14 1 153614255-153616986 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA027613 Supported Supported Nuclear bodies
Cell Junctions
Cytosol Mixed Tissue enhanced esophagus: 2214.5 skin: 592.3 S100A9 60B8AG, CAGB, CFAG, CGLB, LIAG, MAC387, MIF, MRP14, NIF, P14 ENSG00000163220 S100 calcium binding protein A9 1 153357854-153361027 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004193, CAB009441 Supported Supported Nucleoplasm
Cell Junctions
Cytosol Liver cancer:1.13e-6 (unfavourable), Renal cancer:8.10e-4 (unfavourable) Expressed in all Group enriched 6 bone marrow: 21012.0;esophagus: 24343.4 tonsil: 4079.1 SAMD4A DKFZP434H0350, hSmaug1, KIAA1053, SAMD4, Smaug, SMG, SMGA ENSG00000020577 Sterile alpha motif domain containing 4A 14 54567097-54793315 Predicted intracellular proteins Evidence at protein level HPA043061, HPA065309 Approved Approved Cell Junctions
Cytosol Expressed in all Tissue enhanced testis: 102.3 skeletal muscle: 32.7 SAPCD1 C6orf26, NG23 ENSG00000228727 Suppressor APC domain containing 1 6 31762799-31764851 Predicted intracellular proteins Evidence at transcript level HPA071699 Approved Vesicles
Cell Junctions Mixed Tissue enhanced skin: 3.2 bone marrow: 1.0 SCAMP1 SCAMP37 ENSG00000085365 Secretory carrier membrane protein 1 5 78360583-78479071 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044753 Approved Nucleoplasm
Vesicles
Cell Junctions Renal cancer:1.92e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 69.4 SCN8A CerIII, MED, NaCh6, Nav1.6, PN4 ENSG00000196876 Sodium channel, voltage gated, type VIII alpha subunit 12 51590266-51812864 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022169 Supported Vesicles
Cell Junctions Mixed Tissue enriched 6 cerebral cortex: 22.1 testis: 3.5 SCRIB KIAA0147, SCRB1, Vartul ENSG00000180900 Scribbled planar cell polarity protein 8 143790920-143815379 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB015463, CAB022081, HPA023557, HPA064312 Supported Validated Nucleoplasm
Plasma membrane
Cell Junctions
Rods & Rings Expressed in all Expressed in all skin: 22.0 SHKBP1 PP203, Sb1 ENSG00000160410 SH3KBP1 binding protein 1 19 40576851-40591399 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041887 Uncertain Approved Cell Junctions Expressed in all Expressed in all spleen: 54.3 SHROOM2 APXL ENSG00000146950 Shroom family member 2 X 9786456-9949443 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051646 Approved Approved Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.35e-7 (favourable) Expressed in all Mixed cerebral cortex: 11.8 SLC16A1 MCT, MCT1 ENSG00000155380 Solute carrier family 16 (monocarboxylate transporter), member 1 1 112911847-112957013 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA003324, CAB017489, HPA071055 Supported Validated Plasma membrane
Cell Junctions Renal cancer:6.78e-8 (unfavourable), Endometrial cancer:8.37e-6 (unfavourable), Pancreatic cancer:2.10e-4 (unfavourable), Lung cancer:4.05e-4 (unfavourable) Expressed in all Mixed testis: 32.0 SLC16A10 MCT10, TAT1 ENSG00000112394 Solute carrier family 16 (aromatic amino acid transporter), member 10 6 111087503-111231194 Predicted membrane proteins, Transporters Evidence at protein level HPA016860 Approved Approved Vesicles
Cell Junctions Tissue enriched Tissue enhanced placenta: 38.2 skin: 22.5 SLC16A9 C10orf36, FLJ43803, MCT9 ENSG00000165449 Solute carrier family 16, member 9 10 59650761-59736002 Predicted membrane proteins, Transporters Evidence at protein level HPA049286 Approved Approved Nucleus
Cell Junctions Renal cancer:2.56e-6 (favourable) Mixed Tissue enhanced adrenal gland: 199.5;kidney: 199.2 spleen: 57.0 SLC23A3 FLJ31168, SVCT3, Yspl1 ENSG00000213901 Solute carrier family 23, member 3 2 219161465-219170095 Predicted membrane proteins, Transporters Evidence at protein level HPA019059 Approved Nucleus
Cell Junctions Tissue enriched Tissue enhanced kidney: 52.7;small intestine: 23.3 duodenum: 9.0 SLC26A9 ENSG00000174502 Solute carrier family 26 (anion exchanger), member 9 1 205913048-205943460 Predicted membrane proteins, Transporters Evidence at protein level HPA051485 Approved Approved Nucleus
Cell Junctions Head and neck cancer:8.55e-5 (favourable) Tissue enhanced Tissue enhanced salivary gland: 31.7;stomach: 30.4 lung: 11.4 SLC2A11 GLUT10, GLUT11 ENSG00000133460 Solute carrier family 2 (facilitated glucose transporter), member 11 22 23856703-23886309 Predicted membrane proteins, Transporters Evidence at transcript level HPA042960, HPA071184 Uncertain Uncertain Nucleus
Cell Junctions Renal cancer:5.77e-7 (favourable), Pancreatic cancer:3.83e-4 (favourable) Mixed Mixed parathyroid gland: 10.7 SLC2A12 GLUT12, GLUT8 ENSG00000146411 Solute carrier family 2 (facilitated glucose transporter), member 12 6 133988697-134052636 Predicted membrane proteins, Transporters Evidence at protein level HPA031593, HPA031594 Approved Validated Plasma membrane
Cell Junctions Tissue enriched Tissue enhanced prostate: 38.8 endometrium: 15.7 SLC38A6 NAT-1 ENSG00000139974 Solute carrier family 38, member 6 14 60981114-61083733 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018508 Approved Approved Plasma membrane
Cell Junctions
Microtubules Liver cancer:9.47e-6 (unfavourable), Renal cancer:1.37e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 24.3 SLC44A2 CTL2 ENSG00000129353 Solute carrier family 44 (choline transporter), member 2 19 10602457-10644559 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA003228, HPA070799 Approved Approved Vesicles
Cell Junctions Renal cancer:1.71e-5 (favourable), Pancreatic cancer:6.01e-4 (unfavourable) Expressed in all Expressed in all placenta: 224.3 SLC5A6 SMVT ENSG00000138074 Solute carrier family 5 (sodium/multivitamin and iodide cotransporter), member 6 2 27199587-27212958 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA036958 Approved Approved Cell Junctions Renal cancer:3.60e-7 (unfavourable) Expressed in all Expressed in all epididymis: 82.1 SLC5A7 CHT1, hCHT ENSG00000115665 Solute carrier family 5 (sodium/choline cotransporter), member 7 2 107986523-108013994 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046105 Approved Nuclear bodies
Cell Junctions
Intermediate filaments Tissue enhanced Mixed thyroid gland: 2.0 SLC6A6 TAUT ENSG00000131389 Solute carrier family 6 (neurotransmitter transporter), member 6 3 14402576-14489349 Predicted membrane proteins, Transporters Evidence at protein level HPA015028, HPA016488 Supported Approved Cell Junctions
Cytosol Glioma:1.09e-7 (unfavourable), Endometrial cancer:5.22e-5 (favourable), Liver cancer:8.78e-4 (unfavourable) Expressed in all Mixed ovary: 50.7 SLC7A2 ATRC2, CAT-2, HCAT2 ENSG00000003989 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 8 17497088-17570573 Predicted membrane proteins, Transporters Evidence at protein level HPA009277 Supported Plasma membrane
Cell Junctions Renal cancer:2.65e-7 (unfavourable), Stomach cancer:3.08e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 373.7 liver: 92.6 SLC9A2 NHE2 ENSG00000115616 Solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2 2 102619707-102711318 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035121, HPA035122 Approved Approved Cell Junctions Mixed Tissue enhanced colon: 20.9;rectum: 23.7;stomach: 25.8 testis: 10.6 SLC9B2 FLJ23984, NHA2, NHEDC2 ENSG00000164038 Solute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2 4 103019868-103085829 Predicted membrane proteins, Transporters Evidence at protein level HPA047008 Uncertain Approved Nucleoplasm
Cell Junctions Expressed in all Tissue enhanced cerebral cortex: 32.6 liver: 20.5 SLCO4A1 OATP-E, OATP4A1, SLC21A12 ENSG00000101187 Solute carrier organic anion transporter family, member 4A1 20 62642445-62685785 Predicted membrane proteins, Transporters Evidence at protein level HPA030669, HPA030670 Uncertain Approved Cell Junctions Lung cancer:4.74e-4 (unfavourable) Expressed in all Mixed esophagus: 10.6 SLIT3 MEGF5, SLIL2, Slit-3, SLIT1, slit2 ENSG00000184347 Slit guidance ligand 3 5 168661733-169301129 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA051630 Approved Approved Cell Junctions Renal cancer:2.45e-5 (unfavourable) Mixed Mixed parathyroid gland: 98.0 SLX4 BTBD12, FANCP, KIAA1784, KIAA1987 ENSG00000188827 SLX4 structure-specific endonuclease subunit 16 3581181-3611598 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA049421, HPA066238 Approved Supported Nucleoplasm
Cell Junctions
Cytosol Expressed in all Tissue enhanced testis: 12.8 lymph node: 4.9 SMPD2 ISC1, nSMase ENSG00000135587 Sphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase) 6 109440763-109443919 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018110, HPA018125 Uncertain Approved Vesicles
Plasma membrane
Cell Junctions Liver cancer:1.17e-4 (unfavourable), Urothelial cancer:1.70e-4 (favourable), Pancreatic cancer:1.00e-3 (favourable) Expressed in all Mixed testis: 55.6 SNRK FLJ20224, HSNFRK, KIAA0096 ENSG00000163788 SNF related kinase 3 43286512-43424764 Enzymes, Predicted intracellular proteins Evidence at protein level HPA042163 Uncertain Approved Nucleus
Vesicles
Plasma membrane
Cell Junctions Renal cancer:9.41e-5 (favourable), Breast cancer:9.28e-4 (favourable) Expressed in all Expressed in all placenta: 47.5 SNX32 FLJ30934, SNX6B ENSG00000172803 Sorting nexin 32 11 65833641-65856896 Predicted intracellular proteins Evidence at protein level HPA041775 Uncertain Uncertain Cell Junctions
Focal adhesion sites Mixed Tissue enhanced cerebral cortex: 7.8 testis: 1.7 SORL1 C11orf32, gp250, LR11, LRP9, SorLA, SorLA-1 ENSG00000137642 Sortilin-related receptor, L(DLR class) A repeats containing 11 121452203-121633693 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011500, HPA031321 Uncertain Approved Nucleoplasm
Cell Junctions Renal cancer:1.80e-7 (favourable) Expressed in all Mixed cervix, uterine: 67.4 SPERT CBY2, NURIT ENSG00000174015 Spermatid associated 13 45702311-45714559 Predicted intracellular proteins Evidence at protein level HPA039359, HPA040046 Supported Approved Plasma membrane
Cell Junctions Mixed Tissue enriched 175 testis: 49.2 fallopian tube,urinary bladder: 0.2 SPN CD43, GPL115, LSN ENSG00000197471 Sialophorin 16 29662979-29670876 CD markers, Predicted membrane proteins Evidence at protein level CAB002666, HPA055244 Supported Uncertain Golgi apparatus
Plasma membrane
Cell Junctions Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 38.7;lung: 33.4 lymph node: 25.8 SPTBN2 SCA5 ENSG00000173898 Spectrin, beta, non-erythrocytic 2 11 66685248-66729226 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009844, HPA039293, HPA043529 Supported Supported Cell Junctions
Cytosol Pancreatic cancer:3.14e-5 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 73.2;skin: 59.4;testis: 48.5 parathyroid gland: 24.2 SRCIN1 KIAA1684, p140Cap, SNIP ENSG00000277363 SRC kinase signaling inhibitor 1 17 38530016-38605930 Predicted intracellular proteins Evidence at protein level HPA009701, HPA063795 Approved Approved Cell Junctions Urothelial cancer:1.76e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 22.2 skin: 4.7 SSX2IP ENSG00000117155 Synovial sarcoma, X breakpoint 2 interacting protein 1 84643707-84690803 Predicted intracellular proteins Evidence at protein level HPA027306, HPA075946 Approved Approved Cell Junctions Colorectal cancer:1.45e-4 (favourable) Expressed in all Tissue enhanced testis: 191.0 cerebral cortex: 45.9 SYNPO2L FLJ12921 ENSG00000166317 Synaptopodin 2-like 10 73644881-73663803 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA055192, HPA057142 Supported Approved Nuclear speckles
Cell Junctions
Cytosol Group enriched Group enriched 11 heart muscle: 158.4;skeletal muscle: 96.0 esophagus: 11.2 SYT8 DKFZp434K0322 ENSG00000149043 Synaptotagmin VIII 11 1828307-1837521 Predicted membrane proteins Evidence at transcript level HPA052700 Uncertain Approved Nucleoplasm
Cell Junctions Tissue enhanced Group enriched 5 gallbladder: 26.7;skin: 80.3;urinary bladder: 25.5 seminal vesicle: 8.5 TBC1D24 DFNA65, DFNB86, KIAA1171, TLDC6 ENSG00000162065 TBC1 domain family, member 24 16 2475118-2505734 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA044712, HPA068080 Uncertain Supported Plasma membrane
Cell Junctions Breast cancer:3.22e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 23.4 TCAF2 FAM115C, FAM139A, FLJ40722 ENSG00000170379 TRPM8 channel-associated factor 2 7 143620950-143730409 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038756, HPA038758 Uncertain Supported Endoplasmic reticulum
Plasma membrane
Cell Junctions Renal cancer:4.17e-6 (unfavourable), Glioma:6.78e-5 (unfavourable) Mixed Mixed placenta: 8.4 TCEB1 SIII ENSG00000154582 Transcription elongation factor B (SIII), polypeptide 1 (15kDa, elongin C) 8 73939169-73972287 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA078113 Approved Cell Junctions Breast cancer:6.48e-4 (unfavourable) Expressed in all Expressed in all testis: 162.2 TES DKFZP586B2022, TESS-2, TESTIN ENSG00000135269 Testin LIM domain protein 7 116210493-116258783 Predicted intracellular proteins Evidence at protein level HPA015269, HPA018123 Approved Supported Plasma membrane
Cell Junctions
Focal adhesion sites
Cytosol Pancreatic cancer:1.20e-5 (unfavourable), Renal cancer:8.71e-5 (favourable) Expressed in all Expressed in all seminal vesicle: 269.2 TEX14 CT113 ENSG00000121101 Testis expressed 14 17 58556678-58692055 Enzymes, Predicted intracellular proteins Evidence at protein level HPA030620 Approved Vesicles
Plasma membrane
Cell Junctions
Cytosol Mixed Tissue enriched 43 testis: 49.0 bone marrow: 1.1 TIAM1 ENSG00000156299 T-cell lymphoma invasion and metastasis 1 21 31118416-31559977 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB010416, HPA034853 Uncertain Approved Nucleoplasm
Nuclear membrane
Cell Junctions
Cytosol Mixed Mixed esophagus: 21.6 TJP1 DKFZp686M05161, MGC133289, ZO-1 ENSG00000104067 Tight junction protein 1 15 29699367-29968865 Predicted intracellular proteins Evidence at protein level HPA001636, HPA001637, CAB010822 Supported Validated Cell Junctions Renal cancer:1.72e-4 (favourable) Expressed in all Mixed cerebral cortex: 49.8 TJP2 DFNA51, X104, ZO-2, ZO2 ENSG00000119139 Tight junction protein 2 9 69121264-69255208 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001813, CAB009228 Supported Validated Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.78e-14 (favourable) Expressed in all Expressed in all parathyroid gland: 136.2 TJP3 ZO-3 ENSG00000105289 Tight junction protein 3 19 3708109-3750813 Predicted intracellular proteins Evidence at protein level CAB013244, HPA046863, HPA053337 Supported Validated Nucleoplasm
Cell Junctions Renal cancer:9.36e-8 (favourable), Endometrial cancer:1.83e-6 (favourable), Head and neck cancer:9.52e-4 (favourable) Mixed Tissue enhanced duodenum: 42.7;small intestine: 42.1 colon: 31.1 TM4SF5 ENSG00000142484 Transmembrane 4 L six family member 5 17 4771884-4783213 Predicted membrane proteins Evidence at protein level HPA055674 Uncertain Nucleoplasm
Plasma membrane
Cell Junctions Tissue enriched Group enriched 5 duodenum: 181.8;small intestine: 172.8 liver: 33.2 TMEM141 MGC14141 ENSG00000244187 Transmembrane protein 141 9 136791355-136793257 Predicted membrane proteins Evidence at protein level HPA014615, HPA050244 Approved Supported Cell Junctions
Mitochondria Renal cancer:6.63e-4 (favourable) Expressed in all Expressed in all prostate: 214.3 TMEM164 FLJ22679, RP13-360B22.2 ENSG00000157600 Transmembrane protein 164 X 110002631-110182734 Predicted membrane proteins Evidence at protein level HPA038784 Approved Approved Vesicles
Cell Junctions Liver cancer:8.17e-6 (unfavourable), Stomach cancer:3.14e-4 (favourable) Expressed in all Expressed in all lung: 26.7 TMEM183A C1orf37 ENSG00000163444 Transmembrane protein 183A 1 203007386-203024848 Predicted membrane proteins Evidence at protein level HPA072607 Approved Nucleus
Plasma membrane
Cell Junctions Liver cancer:2.62e-4 (unfavourable) Expressed in all Expressed in all testis: 58.5 TMEM186 C16orf51, DKFZP564K2062 ENSG00000184857 Transmembrane protein 186 16 8780384-8797648 Predicted membrane proteins Evidence at protein level HPA018226, HPA063559 Uncertain Approved Cell Junctions Renal cancer:1.93e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 22.5 TMEM251 C14orf109, DKFZP564F1123 ENSG00000153485 Transmembrane protein 251 14 93184951-93187089 Predicted membrane proteins Evidence at transcript level HPA048559 Uncertain Approved Golgi apparatus
Cell Junctions Liver cancer:6.14e-7 (unfavourable), Renal cancer:1.10e-4 (favourable) Expressed in all Expressed in all prostate: 27.9 TMPRSS2 PRSS10 ENSG00000184012 Transmembrane protease, serine 2 21 41464551-41531116 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034493, HPA035787 Supported Supported Nucleoplasm
Cell Junctions Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable) Tissue enriched Tissue enhanced prostate: 495.7 stomach: 142.5 TNFRSF25 APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR ENSG00000215788 Tumor necrosis factor receptor superfamily, member 25 1 6461151-6466195 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA077620 Approved Cell Junctions Renal cancer:1.65e-7 (unfavourable), Head and neck cancer:3.09e-4 (favourable), Colorectal cancer:4.46e-4 (unfavourable) Expressed in all Tissue enhanced skin: 29.7 spleen: 12.3 TNK1 ENSG00000174292 Tyrosine kinase, non-receptor, 1 17 7380534-7389774 Enzymes, Predicted intracellular proteins Evidence at protein level HPA012065, HPA056452 Uncertain Approved Cell Junctions Urothelial cancer:1.52e-4 (favourable), Endometrial cancer:4.28e-4 (favourable), Renal cancer:6.40e-4 (favourable) Mixed Mixed skin: 10.3 TP53BP2 53BP2, ASPP2, PPP1R13A ENSG00000143514 Tumor protein p53 binding protein 2 1 223779899-223845972 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA021603, HPA050429 Supported Validated Cell Junctions
Cytosol Expressed in all Expressed in all thyroid gland: 34.4 TPD52L1 D53, hD53 ENSG00000111907 Tumor protein D52-like 1 6 125119049-125264407 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA027915, HPA027916 Approved Approved Plasma membrane
Cell Junctions
Cytosol Renal cancer:3.26e-4 (favourable), Thyroid cancer:3.97e-4 (favourable), Urothelial cancer:5.34e-4 (unfavourable) Expressed in all Tissue enhanced adrenal gland: 321.3 salivary gland: 126.8 TRIM38 RNF15, RORET ENSG00000112343 Tripartite motif containing 38 6 25962802-25991226 Predicted intracellular proteins Evidence at protein level HPA031685 Approved Approved Plasma membrane
Cell Junctions
Centrosome Urothelial cancer:4.94e-9 (favourable), Thyroid cancer:8.20e-5 (favourable), Ovarian cancer:8.95e-5 (favourable) Expressed in all Mixed spleen: 20.1 TSR2 DT1P1A10, RP1-112K5.2, WGG1 ENSG00000158526 TSR2, 20S rRNA accumulation, homolog (S. cerevisiae) X 54440401-54445487 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA030514 Approved Approved Nucleus
Nucleoli
Cell Junctions
Cytosol Renal cancer:1.21e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 88.7 TSSK4 C14orf20, STK22E ENSG00000139908 Testis-specific serine kinase 4 14 24205697-24208362 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060660 Approved Cell Junctions Mixed Tissue enhanced testis: 42.8 parathyroid gland: 10.8 UBALD1 FAM100A ENSG00000153443 UBA-like domain containing 1 16 4608883-4615027 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA066771 Approved Approved Nucleus
Cell Junctions
Cytosol Expressed in all Expressed in all cerebral cortex: 23.9 UBXN10 FLJ25429, UBXD3 ENSG00000162543 UBX domain protein 10 1 20186085-20196048 Predicted intracellular proteins Evidence at protein level HPA028555, HPA028564 Uncertain Uncertain Nucleoplasm
Plasma membrane
Cell Junctions Glioma:1.64e-4 (unfavourable), Endometrial cancer:2.02e-4 (favourable) Mixed Tissue enhanced fallopian tube: 78.2 testis: 25.4 VASP ENSG00000125753 Vasodilator-stimulated phosphoprotein 19 45506579-45526983 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004612, HPA005724 Supported Supported Plasma membrane
Cell Junctions
Focal adhesion sites Renal cancer:5.91e-7 (unfavourable), Liver cancer:3.49e-5 (unfavourable) Expressed in all Expressed in all appendix: 93.1 VCAM1 CD106 ENSG00000162692 Vascular cell adhesion molecule 1 1 100719742-100739045 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB000154, HPA034796, HPA069867 Supported Approved Cell Junctions Head and neck cancer:7.19e-5 (favourable), Cervical cancer:3.82e-4 (favourable) Tissue enriched Tissue enriched 5 spleen: 557.0 lymph node: 111.2 VPS13B CHS1, COH1 ENSG00000132549 Vacuolar protein sorting 13 homolog B (yeast) 8 99013266-99877580 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043865 Approved Cell Junctions Expressed in all Mixed parathyroid gland: 14.4 VPS36 C13orf9, CGI-145, Eap45 ENSG00000136100 Vacuolar protein sorting 36 homolog (S. cerevisiae) 13 52412602-52450628 Predicted intracellular proteins Evidence at protein level HPA039734, HPA043947 Approved Supported Vesicles
Lysosomes
Plasma membrane
Cell Junctions Renal cancer:9.91e-6 (favourable) Expressed in all Expressed in all skin: 62.6 VTCN1 B7-H4, B7H4, B7S1, B7X, FLJ22418 ENSG00000134258 V-set domain containing T cell activation inhibitor 1 1 117143587-117210960 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054200 Approved Approved Plasma membrane
Cell Junctions
Focal adhesion sites Group enriched Tissue enhanced breast: 127.6;fallopian tube: 50.8 cervix, uterine: 21.9 WDPCP BBS15, C2orf86, fritz, hFrtz ENSG00000143951 WD repeat containing planar cell polarity effector 2 63121383-63827843 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA044144 Uncertain Approved Cell Junctions Mixed Mixed testis: 11.9 WRAP73 WDR8 ENSG00000116213 WD repeat containing, antisense to TP73 1 3630767-3652761 Predicted intracellular proteins Evidence at protein level HPA026893 Uncertain Approved Nucleoplasm
Cell Junctions Liver cancer:1.37e-4 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:3.49e-4 (favourable) Expressed in all Expressed in all lymph node: 20.7 XRCC6BP1 KUB3 ENSG00000166896 XRCC6 binding protein 1 12 57941541-57957269 Enzymes, Predicted intracellular proteins Evidence at protein level HPA035804, HPA043204 Uncertain Validated Vesicles
Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.44e-5 (unfavourable) Expressed in all Tissue enhanced testis: 26.6 rectum: 5.6 ZDHHC5 KIAA1748, ZNF375 ENSG00000156599 Zinc finger, DHHC-type containing 5 11 57667747-57701187 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014670 Approved Approved Nucleoplasm
Plasma membrane
Cell Junctions
Cytosol Pancreatic cancer:6.74e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 86.1 ZNF236 ENSG00000130856 Zinc finger protein 236 18 76822607-76970727 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA008600 Uncertain Approved Nucleoplasm
Cell Junctions
Cytosol Expressed in all Mixed testis: 13.2 ZNF497 FLJ44773 ENSG00000174586 Zinc finger protein 497 19 58354357-58362848 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA047872 Uncertain Approved Nucleus
Cell Junctions Mixed Mixed fallopian tube: 10.7 ZNF688 ENSG00000229809 Zinc finger protein 688 16 30569346-30572734 Predicted intracellular proteins Evidence at transcript level HPA048922 Uncertain Approved Nucleoplasm
Plasma membrane
Cell Junctions Endometrial cancer:4.58e-5 (favourable), Lung cancer:3.24e-4 (favourable), Breast cancer:5.90e-4 (favourable), Pancreatic cancer:6.61e-4 (favourable), Cervical cancer:7.74e-4 (favourable) Expressed in all Expressed in all testis: 23.9